THERAPY DOSSIER · th-dbc96e1ba57f

Mesenchymal stem cells (MSCs) or MSC-conditioned medium

Biologic · Cell therapy (MSCs or MSC-conditioned medium); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (MSCs or MSC-conditioned medium); not a ChEMBL entity
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05887804 ↗PHASE4completed

UC-MSC, Its Conditioned Medium, and Triamcinolone as Keloid Therapy

Keloid

Enrolment: 24 · Results not recorded

NCT03676400 ↗NAcompleted

Conditioned Media of Cord Blood-derived Stem Cells for Androgenic Alopecia

Androgenic Alopecia

Enrolment: 84 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23138401 ↗2012Reported benefit

Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury.

RatOtherSprague-Dawleymale and femaleIntratrachealSingle dose on postnatal day 9, after hyperoxic injury was established

Model: Neonatal hyperoxia-induced lung injury from postnatal day 2 to day 16

Both mesenchymal stem cells and conditioned medium improved alveolar and vascular development at all time points with reduced inflammatory mediator expression, and at postnatal day 100 the improvement was greater with cells than with conditioned medium.

Extraction: extract · Supplied extraction confidence: 0.78. Machine-extracted fields require source verification.

Loading the evidence…